AUA2025: Key Takeaways: Endourology/Stones Highlights

Anorectal Malformation AUA Urology Core Curriculum: auau.auanet.org/core Host: Mark L. Gonzalez, MD, PhD, MBA Guests: Christina Ho, MD and Molly E. Fuchs, MD Outline: Segment 1: Anorectal Malformation Overview/Background Segment 2: Initial Evaluation and Management Segment 3: Cloacal Malformations Segment 4: Long-Term Bladder Management & Concern for CKD Segment 5: Other Considerations

AUA2025: Key Takeaways: Endourology/Stones Highlights Presenters: Davis Viprakasit, MD & Stephen Nakada MD, FACS, FRCS

Update Series (2025) Lesson 30: Beyond Ureteropelvic Junction: Case-Based Tips and Tricks in Robotic Ureteral Stricture Reconstructive Surgery Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25

The Latest Breakthroughs in LG-IR-NMIBC (2025) CME Available: auau.auanet.org/node/43689 After participating in this CME activity, participants will be able to: 1. Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes. 2. Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns. 3. Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments. 4. Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval). 5. Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies. 6. Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery. ACKNOWLEDGEMENTS Support provided by an independent educational grant from: UroGen Pharma, Inc.

The Latest Breakthroughs in mHSPC CME Available: https://auau.auanet.org/node/43825 After participating in this CME activity, participants will be able to: 1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC. 2.Implement current clinical guidelines for biomarker testing in mHSPC. 3.Explain the role of the PI3K/AKT pathway in prostate cancer biology. 4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC. 5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC. Acknowledgements: AstraZeneca Bayer HealthCare Pharmaceuticals Inc.

AUA2025: Key Takeaways: Sexual Dysfunction Highlights Presenter: Brittany Berk, MD & Arthur Burnett, MD, MBA

AUA2025: Key Takeaways: Female Urology Highlights Presenter: Mitch G. Goldenberg, MD & Kathleen Kobashi, MD, MBA, FACS

AUA2025: John Duckett Memorial Lecture: Obstructive Bladder Disease: Molecular Insights and Therapeutic Opportunities Presenter: Rosalyn M. Adam, PhD

AUA2025: Ramon Guiteras Lecture: The Future of Healthcare: How Will Urology be Impacted? Presenter: Vin Gupta, MD, MPA

AUA2025: John K Lattimer Lecture: Telesurgery Presenter: Vipul Patel, MD